Axon Enterprise, Inc (NASDAQ:AXON) Shares Sold by Oak Thistle LLC

Oak Thistle LLC trimmed its stake in shares of Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 28.3% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,027 shares of the biotechnology company's stock after selling 406 shares during the period. Oak Thistle LLC's holdings in Axon Enterprise were worth $540,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Pinion Investment Advisors LLC grew its holdings in Axon Enterprise by 3.0% during the 1st quarter. Pinion Investment Advisors LLC now owns 649 shares of the biotechnology company's stock valued at $341,000 after buying an additional 19 shares in the last quarter. Kentucky Retirement Systems increased its position in Axon Enterprise by 0.4% in the first quarter. Kentucky Retirement Systems now owns 4,953 shares of the biotechnology company's stock worth $2,605,000 after purchasing an additional 19 shares during the last quarter. WCM Investment Management LLC lifted its position in Axon Enterprise by 0.8% during the first quarter. WCM Investment Management LLC now owns 2,441 shares of the biotechnology company's stock valued at $1,306,000 after purchasing an additional 19 shares during the last quarter. HBK Sorce Advisory LLC grew its stake in shares of Axon Enterprise by 4.6% in the 1st quarter. HBK Sorce Advisory LLC now owns 451 shares of the biotechnology company's stock worth $237,000 after buying an additional 20 shares in the last quarter. Finally, Prudent Man Advisors LLC grew its stake in shares of Axon Enterprise by 1.6% in the 1st quarter. Prudent Man Advisors LLC now owns 1,298 shares of the biotechnology company's stock worth $683,000 after buying an additional 20 shares in the last quarter. 79.08% of the stock is currently owned by institutional investors.

Insider Transactions at Axon Enterprise

In other Axon Enterprise news, Director Michael Garnreiter sold 5,913 shares of Axon Enterprise stock in a transaction on Wednesday, June 4th. The shares were sold at an average price of $760.00, for a total value of $4,493,880.00. Following the transaction, the director directly owned 17,740 shares of the company's stock, valued at approximately $13,482,400. The trade was a 25.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Caitlin Elizabeth Kalinowski sold 1,300 shares of the firm's stock in a transaction on Monday, May 19th. The stock was sold at an average price of $738.84, for a total value of $960,492.00. Following the completion of the transaction, the director owned 4,829 shares of the company's stock, valued at $3,567,858.36. This trade represents a 21.21% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 34,642 shares of company stock worth $25,090,528. Insiders own 4.40% of the company's stock.

Axon Enterprise Trading Up 3.6%

Shares of NASDAQ AXON traded up $25.75 during trading hours on Friday, reaching $735.01. The stock had a trading volume of 654,601 shares, compared to its average volume of 627,317. Axon Enterprise, Inc has a 52-week low of $279.02 and a 52-week high of $830.21. The firm has a market cap of $57.22 billion, a price-to-earnings ratio of 177.54, a P/E/G ratio of 79.06 and a beta of 1.29. The business's fifty day moving average price is $763.82 and its two-hundred day moving average price is $650.42. The company has a current ratio of 2.83, a quick ratio of 2.62 and a debt-to-equity ratio of 0.68.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.34 by $0.07. Axon Enterprise had a return on equity of 5.81% and a net margin of 14.86%. The business had revenue of $603.63 million for the quarter, compared to the consensus estimate of $585.67 million. During the same quarter in the prior year, the company earned $1.15 EPS. The business's revenue was up 31.3% compared to the same quarter last year. Analysts expect that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. JMP Securities increased their price target on shares of Axon Enterprise from $725.00 to $825.00 and gave the company a "market outperform" rating in a report on Tuesday. Morgan Stanley set a $885.00 target price on Axon Enterprise and gave the company an "overweight" rating in a research report on Friday, July 11th. Needham & Company LLC lifted their price objective on shares of Axon Enterprise from $600.00 to $750.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th. UBS Group began coverage on shares of Axon Enterprise in a report on Wednesday, July 16th. They issued a "neutral" rating and a $820.00 target price for the company. Finally, JPMorgan Chase & Co. upped their price target on shares of Axon Enterprise from $730.00 to $850.00 and gave the company an "overweight" rating in a report on Thursday, July 17th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $772.08.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.